StockNews.com upgraded shares of CEL-SCI (NYSEAMERICAN:CVM – Free Report) from a sell rating to a hold rating in a research note released on Saturday. Separately, EF Hutton Acquisition Co. I restated a buy rating and issued a $10.00 price objective on shares of CEL-SCI in a research note on Thursday, March 9th. CEL-SCI Trading Up […]
Related Keywords
, Goldman Sachs Group Inc , A Davidson , Ef Hutton Acquisition Co , Walleye Capital , Da Davidson , Renaissance Technologies , Millennium Management , Free Report , Sachs Group , Leukocyte Interleukin , Cel Sci , Nyseamerican Cvm , Icvm , Medical , Upgrade , Stocknews Com ,
comparemela.com © 2020. All Rights Reserved.